Document Detail

Comparison between three- and six-month postoperative refractive and visual results after laser epithelial keratomileusis with mitomycin C.
MedLine Citation:
PMID:  18774546     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To compare the residual refraction and visual results between the three- and six-month postoperative visits to detect the optimal moment for enhancement after myopic laser epithelial keratomileusis (LASEK) with mitomycin C (MMC). DESIGN: Nonrandomized, interventional, prospective study. METHODS: One hundred and forty-one consecutive eyes that underwent LASEK with MMC to correct their myopia using the Esiris excimer laser (Schwind Eye Tech Solutions, Kleinostheim, Germany), and that showed three months postoperatively a residual defect or a suboptimal uncorrected visual acuity (UCVA) or best spectacle-corrected visual acuity (BSCVA) were included in the study. We compared the residual spherical refraction and cylinder, the UCVA, and the BSCVA between the three- and six-month postoperative examinations. RESULTS: Preoperative spherical refraction was -5.2 +/- 2.90 diopters (D). Preoperative cylinder was -1.66 +/- 1.20 D. The residual sphere was +0.43 +/- 0.90 D three months and +0.21 +/- 0.90 D six months after surgery (P = .0001). The cylinder was -0.71 +/- 0.60 D and -0.67 +/- 0.60 D, respectively (P = .4). The UCVA was 0.75 +/- 0.2 and 0.81 +/- 0.2 (P = .0001) and the BSCVA was 0.94 +/- 0.1 and 1.01 +/- 0.1 (P = .0001), respectively. Those patients with a myopic defect (sphere or cylinder) three months postoperatively did not show any significant change in UCVA or refractive defect six months after surgery, while those with a hyperopic defect (sphere or cylinder) showed an improvement in UCVA and residual refraction six months postoperatively (P < .05). CONCLUSIONS: Our results suggest that retreatment after myopic LASEK with MMC may be performed three months after surgery when the residual refraction is myopic, but it seems wise to wait at least six months after surgery when the residual refraction is hyperopic.
Laura de Benito-Llopis; Miguel A Teus; José L Hernández-Verdejo
Related Documents :
14967276 - Outcomes of laser in situ keratomileusis in patients with pigment dispersion syndrome.
16503776 - Risk of endophthalmitis after cataract surgery using different protocols for povidone- ...
11760106 - Comparison of appropriateness ratings for cataract surgery between convened and mail-on...
16647126 - Recalcitrant post-lasik mycobacterium chelonae keratitis eradicated after the use of fo...
8620056 - Apolipoprotein e and complement c3 polymorphism and their role in the response to gemfi...
11933726 - Using an artificial neural network to predict healing times and risk factors for venous...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2008-09-06
Journal Detail:
Title:  American journal of ophthalmology     Volume:  147     ISSN:  1879-1891     ISO Abbreviation:  Am. J. Ophthalmol.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-22     Completed Date:  2009-01-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370500     Medline TA:  Am J Ophthalmol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  71-76.e2     Citation Subset:  AIM; IM    
Vissum Madrid, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alkylating Agents / administration & dosage*
Combined Modality Therapy
Follow-Up Studies
Keratectomy, Subepithelial, Laser-Assisted / methods*
Lasers, Excimer / therapeutic use*
Middle Aged
Mitomycin / administration & dosage*
Myopia / physiopathology,  therapy*
Postoperative Period
Prospective Studies
Refraction, Ocular / physiology*
Time Factors
Visual Acuity / physiology*
Reg. No./Substance:
0/Alkylating Agents; 50-07-7/Mitomycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predicting visual outcome after treatment of pituitary adenomas with optical coherence tomography.
Next Document:  Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month r...